> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Neuronetics Posts $0.5 Million Operating Profit As Greenbrook Clinics Climb 20.1%
- URL: https://www.bullished.co/neuronetics-posts-0-5-million-operating-profit-as-greenbrook-clinics-climb-20-1-646d6421/
- Published: 2026-11-04T13:06:12.000Z
- Updated: 2026-11-04T13:06:12.000Z
- Description: The TMS maker held its 2026 revenue outlook and lowered its spending and cash-burn forecasts after a third quarter that cut its net loss to $1.6 million.
- Author: Matteo Parrino
- Tags: Earnings, STIM, Industry: Healthcare

Neuronetics, which makes the NeuroStar transcranial magnetic stimulation system for depression and runs the Greenbrook treatment clinics, [turned a third-quarter operating profit of $0.5 million](https://www.sec.gov/Archives/edgar/data/0001227636/000119312526446239/d144740d8k.htm?ref=bullished.co) against a $7.3 million operating loss a year earlier, the company said Wednesday. It kept its 2026 revenue forecast and trimmed its spending and cash-burn estimates.

## Clinics drive a 12.5% revenue gain

Total revenue rose 12.5% to $42.0 million, according to the [earnings release](https://www.sec.gov/Archives/edgar/data/0001227636/000119312526446239/d144740dex991.htm?ref=bullished.co). Greenbrook clinic revenue climbed 20.1% to $26.2 million, while NeuroStar device revenue edged up 1.8% to $15.8 million.

Gross margin widened to 52.2% from 45.9%. The company credited its new go-to-market strategy and better billing collections at the Greenbrook clinics.

Operating expenses fell 13% to $21.3 million, mostly on lower sales and marketing costs, partly offset by higher general and administrative spending. Adjusted EBITDA, the company's own profit measure that excludes items such as stock pay and restructuring, was $1.9 million versus a $4.7 million loss. The net loss was $1.6 million versus $9.4 million.

CEO Dan Reuvers said the quarter "showed our strategy taking hold across our business," with a record third quarter at Greenbrook and in NeuroStar system sales.

## Lower spending forecast, same revenue target

For 2026, Neuronetics still expects revenue of $160 million to $164 million. It cut its operating expense forecast to $92.5 million to $95.5 million from $95 million to $100 million.

It narrowed expected gross margin to 49% to 50% from 48% to 50%. Cash flow from operating and investing activities is now forecast at negative $10.0 million to negative $12.0 million, an improvement from negative $10.5 million to negative $14.5 million.

Total cash, including restricted cash, was $27.9 million at September 30, down from $34.1 million at December 31, 2025.

## FDA review and an EHR link

Neuronetics submitted a 510(k) application to the FDA in August for an accelerated TMS protocol, which is under review. It also signed a distribution agreement with Wave Neuroscience and plans to seek clearance to make NeuroStar compatible with Wave's PTSD software.

The company launched an integration of its TrakStar practice platform with AdvancedMD's electronic records system. It is expected to reach existing NeuroStar providers on AdvancedMD in the fourth quarter of 2026.

Reuvers said the company is preparing for psychedelic therapies in its Greenbrook clinics, an offering that depends on FDA approval.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Neuronetics, Inc. (STIM)](https://www.sec.gov/Archives/edgar/data/0001227636/000119312526446239/d144740d8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d144740dex991.htm — Neuronetics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001227636/000119312526446239/d144740dex991.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d144740dex992.htm — Neuronetics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001227636/000119312526446239/d144740dex992.htm?ref=bullished.co) — SEC EDGAR